[{"title": "QRICH1 regulates ATF6 transcription to affect pathological cardiac hypertrophy progression", "link": "https://link.springer.com/article/10.1186/s10020-025-01241-2", "details": "L Zhang, H Chen, G Zou, W Jia, H Dong, C Wang\u2026 - Molecular Medicine, 2025", "abstract": "Many studies have shown that pathological cardiac hypertrophy is associated with active endoplasmic reticulum (ER) stress. Glutamine-rich protein 1 (QRICH1), as a transcriptional regulator, belongs to the caspase recruitment domain (CARD) \u2026"}, {"title": "Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model", "link": "https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf324/8139707", "details": "T Baka, J Moore, F Qin, SR Yurista, A Zhang, H He\u2026 - European Heart Journal, 2025", "abstract": "Abstract Background and Aims Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy (LVH), diastolic dysfunction, and impaired metabolic efficiency. This study investigates the \u2026"}, {"title": "Prevalence of transthyretin amyloid cardiomyopathy in an unselected cohort with heart failure with preserved ejection fraction", "link": "https://link.springer.com/article/10.1007/s12471-025-01954-3", "details": "A Achten, VPM van Empel, J Weerts, S Mourmans\u2026 - Netherlands Heart Journal, 2025", "abstract": "Methods From 2018 to 2023, all patients diagnosed with HFpEF underwent prospective screening for ATTR-CM. Diagnosis of ATTR-CM was made in accordance with guideline recommendations. Results Of the 202 HFpEF patients \u2026"}]
